Close Menu

research and development

Bioinformatics firm M2Gen will analyze whole-exome sequencing and tumor RNA-seq data for the HudsonAlpha genomic lab affiliate.

The Boston-based firm is pursuing nanopore technology as a readout for its unique information-encoding format, which could help customers store vast amounts of data.

In a PrecisionFDA challenge, DeepVariant calls of PacBio HiFi reads topped 99 percent precision and recall for SNVs and indels, bringing HiFi in line with Illumina. 

Applied StemCell, based in the San Francisco Bay Area, will develop and sell CRISPR-based services and reagents under a license from ERS Genomics.

The goal of the project is to build a liquid biopsy-based early detection technology platform and develop tests for lung and digestive system cancers.

Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.

The firm's test detects DNA from tick-borne bacteria directly from a patient's blood, and clinical studies are planned for the 2021 tick season.

The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.

Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK. 

Nvidia customers in the US and the Middle East expect that the newly introduced A100 servers will accelerate research into the novel coronavirus.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.